Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial

Joseph E Tonna, Jan Pierce, Nathan Hatton, Giavonni Lewis, John D Phillips, Alyssa Messina, Chloe R Skidmore, Kirsten Taylor, Craig H Selzman, Joseph E Tonna, Jan Pierce, Nathan Hatton, Giavonni Lewis, John D Phillips, Alyssa Messina, Chloe R Skidmore, Kirsten Taylor, Craig H Selzman

Abstract

Introduction: Human amniotic fluid (hAF) has been shown to reduce inflammation in multiple experimental models. hAF has previously been approved by the US Food and Drug Administration (FDA) as a human cellular and tissue product for tissue injury for human administration, and used safely in thousands of patients as a therapeutic treatment for diverse conditions. Given the profound inflammatory response observed in patients with COVID-19, and the successful completion of 10-patient pilot study of intravenous hAF, we present a trial design for a larger clinical trial of intravenous hAF for the treatment of COVID-19.

Methods and analysis: This paper describes the methodology of a phase I/II randomised, double-blinded, placebo-controlled clinical trial to determine the safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19. Primary outcome will be the change in C-reactive protein. Secondary outcomes include safety, biomarker inflammatory levels and clinically relevant outcomes at 30 days, including mortality, ventilator-free days and hospital and intensive care unit length of stay. Exploratory outcomes of health-related quality-of-life patient-reported outcomes will be collected. Hospitalised patients with laboratory-confirmed COVID-19 will be recruited.

Ethics and dissemination: This study was approved by the University of Utah Institutional Review Board (IRB_0013292), approved by the US FDA under Investigational New Drug (No 23369) and is registered on ClinicalTrials.gov. Results will be disseminated via peer-reviewed publications and conference presentations.

Trial registration number: NCT04497389; Pre-results.

Keywords: COVID-19; clinical trials; intensive & critical care; respiratory medicine (see thoracic medicine).

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Patient screening and enrolment flow chart.

References

    1. Kramer PA, Chacko BK, George DJ, et al. . Decreased bioenergetic health index in monocytes isolated from the pericardial fluid and blood of post-operative cardiac surgery patients. Biosci Rep 2015;35:BSR20150161. 10.1042/BSR20150161
    1. Sirch J, Ledwon M, Püski T, et al. . Active clearance of chest drainage catheters reduces retained blood. J Thorac Cardiovasc Surg 2016;151:832–8. 10.1016/j.jtcvs.2015.10.015
    1. JW D Skin transplantation: with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med J 1910;15:307.
    1. Cargnoni A, Di Marcello M, Campagnol M, et al. . Amniotic membrane patching promotes ischemic rat heart repair. Cell Transplant 2009;18:1147–59. 10.3727/096368909X12483162196764
    1. Kim HG, Choi OH. Neovascularization in a mouse model via stem cells derived from human fetal amniotic membranes. Heart Vessels 2011;26:196–205. 10.1007/s00380-010-0064-6
    1. Food and Drug Administration (FDA) Code of federal regulations, title 21, part 1271. Available: [Accessed 22 Jun 2020].
    1. Marsh KM, Ferng AS, Pilikian T, et al. . Anti-Inflammatory properties of amniotic membrane patch following pericardiectomy for constrictive pericarditis. J Cardiothorac Surg 2017;12:6. 10.1186/s13019-017-0567-7
    1. Pierce J, Jacobson P, Benedetti E, et al. . Collection and characterization of amniotic fluid from scheduled C-section deliveries. Cell Tissue Bank 2016;17:413–25. 10.1007/s10561-016-9572-7
    1. Mohammadi AA, Seyed Jafari SM, Kiasat M, et al. . Effect of fresh human amniotic membrane dressing on graft take in patients with chronic burn wounds compared with conventional methods. Burns 2013;39:349–53. 10.1016/j.burns.2012.07.010
    1. Hao Y, Ma DH, Hwang DG, et al. . Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 2000;19:348–52. 10.1097/00003226-200005000-00018
    1. Koob TJ, Rennert R, Zabek N, et al. . Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 2013;10:493–500. 10.1111/iwj.12140
    1. Brandt FT, Albuquerque CD, Lorenzato FR. Female urethral reconstruction with amnion grafts. Int J Surg Investig 2000;1:409–14.
    1. Burman S, Tejwani S, Vemuganti GK, et al. . Ophthalmic applications of preserved human amniotic membrane: a review of current indications. Cell Tissue Bank 2004;5:161–75. 10.1023/B:CATB.0000046067.25057.0a
    1. Liu B, Li M, Zhou Z, et al. . Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020;111:102452. 10.1016/j.jaut.2020.102452
    1. Chen J, Qi T, Liu L, et al. . Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 2020;80:e1–6. 10.1016/j.jinf.2020.03.004
    1. Yang Y, Shen C, Li J. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome 2020.
    1. Conti P, Ronconi G, Caraffa A, et al. . Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34:327-331. 10.23812/CONTI-E
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Mao Y, Pierce J, Singh-Varma A, et al. . Processed human amniotic fluid retains its antibacterial activity. J Transl Med 2019;17:68. 10.1186/s12967-019-1812-8
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Taichman DB, Sahni P, Pinborg A, et al. . Data Sharing Statements for Clinical Trials - A Requirement of the International Committee of Medical Journal Editors. N Engl J Med 2017;376:2277–9. 10.1056/NEJMe1705439
    1. Foster ED, Deardorff A. Open science framework (OSF). J Med Libr Assoc 2017;105:203–6.
    1. World Health Organization Weekly operational update on COVID-19–9 September 2020. Available: [Accessed 10 Sep 2020].
    1. Emanuel EJ, Persad G, Upshur R. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med 2020.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner